Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-04-2005 | Original Paper

Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells

Authors: Hiroshi Kamiyama, Shingo Takano, Koji Tsuboi, Akira Matsumura

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2005

Abstract

Purpose

Inhibition of angiogenesis is an important new treatment modality for malignancies, including gliomas. Vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1α (HIF-1α) have been investigated as potent mediators of tumor angiogenesis. We investigated whether four major chemotherapeutic agents (ACNU, cisplatin, etoposide, and SN38) showed an angiosuppressive effect in vitro.

Method

The effects of ACNU, cisplatin, etoposide, and SN38 for endothelial cells were assessed by cell growth inhibition assay (WST-8 assay) and vessel formation assay (angiogenesis kit). The inhibitory effects of the HIF-1α and VEGF expression of glioma cells after SN38 treatment were assessed by real-time RT-PCR, Western blot, and ELISA.

Results

SN38, but not other chemotherapeutic agents, selectively inhibited endothelial cell proliferation and three-dimensional tube formations at the 0.01 μM. Furthermore, SN38 significantly decreased the HIF-1α and VEGF expression of glioma cells in a dose- and time-dependent manner under normoxic and hypoxic conditions. SN38 has dual angiosuppressive actions, including both the inhibition of endothelial proliferation and tube formation, and the inhibition of the angiogenic cascade in glioma cells.

Conclusion

SN38 is an attractive agent as both a direct and indirect angiogenesis inhibitor and provides the anti-glioma agents with an angiosuppressive function.

Allegrini G, Goulette AF, Darnowski WJ, Calabresi P (2004) Thrombospondin-1 plus irinotecan: a novel antiangiogenenis-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol 3:261–266

Arthur TW, Vernon ER, Sage EH, Reed JM (1998) Growth factors reverse the impaired sprouting of microvessels from aged mice. Microvasc Res 55:260–270PubMed

Ashby LS, Shapiro WR (2001) Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study. J Neurooncol 51:67–86PubMed

Bacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, Waeber G, Schlegel J (2003) Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol 162:11–17PubMed

Bisacchi D, Bebelli R, Vanzetto C, Ferrari N, Tosetti F, Albini A (2003) Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev 27:229–238PubMed

Brwoder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886PubMed

Buckner JC, Reid JM, Wright K, Kaufmann SH, Erlichman C, Ames M, Cha S, O’Fallon JR, Schaaf LJ, Miller LL (2003) Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer 97:2352–2358PubMed

Carmeliet P, Rakesh JK (2000) Angiogenesis in cancer and other diseases. Nature 14:249–257

Christopher WP, Peter JR (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9:677–684CrossRefPubMed

Clements KM, Jones BC, Cumming M, Daoud SS (1999) Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol 44:411–416CrossRefPubMed

Folkman J (2003) Angiogenesis and proteins of the hemostatic system. J Thromb Haemost 1:1681–1682PubMed

Gasparini G (1999) The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 58:17–38

Hanahan D, Beregers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–1047PubMed

Harris AL (2002) Hypoxia—a key regulatory factor in tumor growth. Nat Rev Cancer 2:38–47PubMed

Hayot C, Farinelle S, De Decker R, Decaestecker C, Darro F, Kiss R, Van Damme M (2002) In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol 21:417–425PubMed

Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727–739PubMed

Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastin and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24PubMed

Kobayashi M, Kondo M, Mitsui Y (1991) Establishment of human endothelial cell lines in a serum-free culture and its application for expression of transfected prepro endothelin gene. Human Cell 4:296–304PubMed

Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW (2004) Hypoxia-inducible factor (HIF-1)α: its protein stability and biological functions. Exp Mol Med 36:1–12PubMed

Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731–2735PubMed

McCrudden KW, Yokoi A, Thosani A, Soffer SZ, Kim ES, Huang J, Manley C, O’toole K, Yamashiro DJ, Kandel JJ, Middlesworth W (2002) Topotecan is anti-angiogenic in experimental hepatoblastoma. J Pediatr Surg 37:857–861PubMed

Nakashio A, Fujita N, Tsuruo T (2002) Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Int J Cancer 98:36–41PubMed

O’Leary J, Muggia MF (1998) Camptothecins: a review of development and schedules of administration. Eur J Cancer 34:1500–1508PubMed

O’Leary J, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M (1999) Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 5:181–187PubMed

Parker JR, Fryehauf PJ, Mehta R, Filka E, Cloughesy T (2004) A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol 66:365–375PubMed

Parney IF, Chang SM (2003) Current chemotherapy for glioblastoma. Cancer J 9:149–156PubMed

Petrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, Marcellini M, Giordano V, Laccabue D, Lanzi C, Zunino F (2003) Antiangiogenic effects of the novel camptothecin ST1481 (Gimatecan) in human tumor xenografts. Mol Cancer Res 1:863–870PubMed

Pili R, Donehower RC (2003) Is HIF-1α a valid therapeutic target?. J Natl Cancer Inst 95:498–499PubMed

Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, Melillo G (2002) Identification of small molecule inhibitors of Hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62:4316–4324PubMed

Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Malillo G (2004) Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64:1475–1482PubMed

Reardon DA, Friedman HS, Powell JB Jr, Gilbert M, Yung WK (2003) Irinotecan: promising activity in the treatment of malignant glioma. Oncology (Huntingt) 17:9–14

Safran M, Kaelin WG Jr (2003) HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 111:779–783PubMed

Schirner M (2000) Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev 19:67–73PubMed

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732CrossRefPubMed

Soffer SZ, Kim E, Moore JT, Huang J, Yokoi A, Manley C, O’Toole K, Middlesworth W, Stolar C, Yamashiro D, Kandel J (2001) Novel use of an established agent: topotecan is anti-angiogenic in experimental Wilms tumor. J Pediatr Surg 36:1781–1784PubMed

Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW (2001) Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 8:638–645PubMed

Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S (1994) Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54:2654–2660PubMed

Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T (1996) Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56:2185–2190PubMed

Takano S, Tsuboi K, Matsumura A, Nose T (2003) Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumor growth and angiogenesis in human glioblastoma xenografts. Neuro-oncol 5:1–7

Tanaka M, Tanaka T, Harata M, Suzuki T, Mitsui Y (1998) Triplet repeat-containing ribosomal protein L14 gene in immortalized human endothelial cell line (t-HUE4). Biochem Biophys Res Commun 243:531–537PubMed

Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22:3213–3220PubMed

Xiao D, Tan W, Li M, Ding J (2001) Antiangiogenic potential of 10-hydroxycamptothecin. Life Sci 69:1619–1628PubMed

Yabushita H, Shimizu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M (2003) Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep 10:89–95PubMed

Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW (2003) YC1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95:516–525PubMed

Yoshida J, Kajita Y, Wakabayashi T, Sugita K (1994) Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumor resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir (Wien) 127:55–59

Zagzag D (1995) Angiogenic growth factors in neural embryogenesis and neoplasia. Am J Pathol 146:293–309PubMed

Title: Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells
Authors: Hiroshi Kamiyama
Shingo Takano
Koji Tsuboi
Akira Matsumura
Publication date: 01-04-2005
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 4/2005
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-004-0642-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2005

Expression of COX-2 and HER-2/neu and estrogen and progesterone receptor in primary squamous cell carcinomas of the endometrium

Heparanase expression correlates with malignant potential in human colon cancer

Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer

Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells

Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation

Human glutathione S-transferase A1, T1, M1, and P1 polymorphisms and susceptibility to prostate cancer in the Japanese population

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials